Black Diamond Therapeutics (BDTX) Return on Capital Employed (2020 - 2026)
Black Diamond Therapeutics (BDTX) posted Return on Capital Employed of 43.15% for Q1 2026, down 564.02% on a QoQ basis from 9.3% in Q4 2025, and down 4013.0% year-over-year from 1.1% in Q1 2025.
Black Diamond Therapeutics (BDTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Black Diamond Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 43.15% for Q1 2026.
- Quarterly Return on Capital Employed fell 4013.0% year-over-year to 43.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.15% (down 4013.0% YoY) and the FY2025 annual result came in at 10.69%, up 7633.0% from the prior year.
- Return on Capital Employed was 43.15% for Q1 2026 at Black Diamond Therapeutics, down from 9.3% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.3% in Q4 2025 and bottomed at 75.17% in Q2 2023.
- A 5-year average of 46.87% and a median of 59.29% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed jumped 8112 bps — and 2026, when it sank 4013 bps.
- Black Diamond Therapeutics' Return on Capital Employed stood at 60.64% in 2022, then advanced by 2 bps to 59.29% in 2023, then retreated by 21 bps to 71.82% in 2024, then surged by 113 bps to 9.3% in 2025, then tumbled by 564 bps to 43.15% in 2026.
- Business Quant data shows BDTX's Return on Capital Employed at 43.15% in Q1 2026, 9.3% in Q4 2025, and 8.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | -43.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.15% |
| Dec 31, 2025 | 9.30% |
| Sep 30, 2025 | 8.09% |
| Jun 30, 2025 | 3.05% |
| Mar 31, 2025 | -3.02% |
| Dec 31, 2024 | -71.82% |
| Sep 30, 2024 | -66.07% |
| Jun 30, 2024 | -68.26% |
| Mar 31, 2024 | -63.69% |
| Dec 31, 2023 | -59.29% |
| Sep 30, 2023 | -66.73% |
| Jun 30, 2023 | -75.17% |
| Mar 31, 2023 | -66.66% |
| Dec 31, 2022 | -60.64% |
| Sep 30, 2022 | -57.61% |
| Jun 30, 2022 | -58.22% |
| Mar 31, 2022 | -56.90% |
| Dec 31, 2021 | -53.47% |
| Sep 30, 2021 | -48.69% |
| Jun 30, 2021 | -38.65% |